Address
Email address
Phone number
We offer top quality molecular biology reagents that are all stable at room temperature!
Name
Solis BioDyne OÜ
Registry code
10242922
VAT number
EE100587614
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
04.08.1997 (27)
Financial year
01.01-31.12
Capital
10 000.00 €
Activity
32991 - Other manufacturing n.e.c.
3 236 964 €
-401 905 €
-12%
3 300 €
(estimate is approximate)
2 713 272 €
45
Submitted
No tax arrears
-15%
-8%
Owner | Representative | Beneficial owner | Roles | |
---|---|---|---|---|
Solis US Invest OÜ 11378730 | 100% - 10 000.00 EUR | - | - | |
Ele Reiljan 07.03.1975 (49) | - | Board member | - | |
Olev Kahre 06.10.1965 (59) | - | - | Indirect ownership | Board member |
Kadri Artma 23.04.1970 (54) | - | - | Indirect ownership | Chairman of the board |
Kaido Padar 14.07.1971 (53) | - | - | - | Board member |
2019 07.05.2020 | 2020 16.03.2021 | 2021 21.03.2022 | 2022 02.05.2023 | 2023 10.04.2024 | |
---|---|---|---|---|---|
Total Revenue | 2 546 868 € | 7 332 677 € | 8 509 793 € | 6 137 990 € | 3 236 964 € |
Net profit (loss) for the period | 709 215 € | 3 756 109 € | 3 281 731 € | 1 029 070 € | -401 905 € |
Profit Margin | 28% | 51% | 39% | 17% | -12% |
Current Assets | 1 422 997 € | 3 934 410 € | 4 641 378 € | 2 557 051 € | 2 494 885 € |
Fixed Assets | 863 606 € | 1 502 534 € | 2 001 716 € | 2 389 134 € | 2 484 699 € |
Total Assets | 2 286 603 € | 5 436 944 € | 6 643 094 € | 4 946 185 € | 4 979 584 € |
Current Liabilities | 228 377 € | 444 917 € | 826 606 € | 651 159 € | 1 241 517 € |
Non Current Liabilities | 496 763 € | 574 455 € | 737 185 € | 1 179 849 € | 1 024 795 € |
Total Liabilities | 725 140 € | 1 019 372 € | 1 563 791 € | 1 831 008 € | 2 266 312 € |
Share Capital | - | - | - | - | - |
Equity | 1 561 463 € | 4 417 572 € | 5 079 303 € | 3 115 177 € | 2 713 272 € |
Employees | 24 | 34 | 56 | 62 | 45 |
Turnover | State taxes | Labor taxes and payments | Employees | |
---|---|---|---|---|
2024 Q1 | 707 207.35 € | 181 179.2 € | 190 406.9 € | 39 |
2023 Q4 | 905 570.19 € | 199 263.13 € | 210 902.16 € | 40 |
2023 Q3 | 749 518.66 € | 258 368.92 € | 271 324.92 € | 40 |
2023 Q2 | 807 713.08 € | 378 013.82 € | 395 096.37 € | 47 |
2023 Q1 | 917 424.15 € | 199 684.4 € | 215 459.16 € | 66 |
2022 Q4 | 1 349 432.74 € | 249 309.05 € | 261 133.3 € | 66 |
2022 Q3 | 1 090 311.72 € | 457 895.66 € | 273 750.79 € | 64 |
2022 Q2 | 1 525 193.48 € | 698 959.97 € | 291 573.24 € | 64 |
2022 Q1 | 2 774 857.41 € | 325 144.59 € | 341 583.88 € | 66 |
2021 Q4 | 1 801 356.36 € | 224 367.7 € | 235 944.36 € | 62 |
2021 Q3 | 1 941 385.63 € | 185 994.03 € | 196 516.2 € | 58 |
2021 Q2 | 3 003 999 € | 859 208.95 € | 170 895.14 € | 53 |
2021 Q1 | 2 169 538.89 € | 285 812.39 € | 304 408.69 € | 49 |
2020 Q4 | 3 733 479.41 € | 188 686.95 € | 102 275.13 € | 45 |
2020 Q3 | 1 206 308.74 € | 123 325.22 € | 131 531.01 € | 36 |
2020 Q2 | 2 261 907.15 € | 190 998.43 € | 89 643.6 € | 33 |
2020 Q1 | 591 702.04 € | 87 840.66 € | 94 035.92 € | 29 |